Oncotarget

Research Papers:

A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one

Se-Il Go, Mi Jung Park, Haa-Na Song, Hoon-Gu Kim, Myoung Hee Kang, Jung Hun Kang, Hye Ree Kim and Gyeong-Won Lee _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:47007-47019. https://doi.org/10.18632/oncotarget.16552

Metrics: PDF 595 views  |   HTML 692 views  |   ?  


Abstract

Se-Il Go1,*, Mi Jung Park2,*, Haa-Na Song3, Hoon-Gu Kim1,4, Myoung Hee Kang1,4, Jung Hun Kang3,4, Hye Ree Kim3 and Gyeong-Won Lee3,4

1Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea

2Department of Radiology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea

3Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea

4Institute of Health Science, Gyeongsang National University College of Medicine, Jinju, Republic of Korea

*These authors have contributed equally to this work

Correspondence to:

Gyeong-Won Lee, email: brightree24@gmail.com

Keywords: sarcopenia, diffuse large B-cell lymphoma, muscle, drug toxicity, prognosis

Received: February 04, 2017    Accepted: February 28, 2017    Published: March 24, 2017

ABSTRACT

Backgrounds: Sarcopenia is known to be associated with poor clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL). There is no consensus concerning the optimal method to define sarcopenia in DLBCL.

Methods: We retrospectively reviewed 193 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Sarcopenia was classified by the region where the pretreatment skeletal muscle index (SMI) was measured.

Results: Both the sarcopenia-L3 and sarcopenia-pectoralis muscle (PM) groups had increased incidences of severe treatment-related toxicities and treatment discontinuation compared with the non-sarcopenia-L3 and non-sarcopenia-PM groups, respectively. The sarcopenia-L3 and non-sarcopenia-L3 groups had 5-year overall survival (OS) rates of 40.5% and 67.8% (p < 0.001), respectively. The sarcopenia-PM and non-sarcopenia-PM groups had 5-year OS rates of 35.9% and 69.0% (p < 0.001), respectively. When the sarcopenia-L3 alone and sarcopenia-PM alone groups were compared, there were no differences in baseline characteristics, treatment toxicity, or survival. In multivariate analysis, when compared with the non-sarcopenia-both group, OS was significantly worse in the sarcopenia-both group (HR, 2.480; 95% CI, 1.284 – 4.792; p = 0.007), but not in patients with either sarcopenia-L3 alone or sarcopenia-PM alone (p = 0.151).

Conclusions: L3- and PM-SMIs are equally useful to define sarcopenia, which is related to intolerance to R-CHOP therapy and to worse survival in patients with DLBCL. More prognostic information can be obtained when these two SMIs are combined to define sarcopenia.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16552